Thursday, Eli Lilly and Co (NYSE:LLY) released topline results from the QWINT-1 and QWINT-3 phase 3 trials evaluating once weekly insulin efsitora alfa (efsitora) in adults with type 2 diabetes.
QWINT-1 evaluated the efficacy and safety of once-weekly efsitora compared to once-daily insulin glargine for 52 weeks in insulin naïve patients.
The trial met its primary endpoint of non-inferior A1C (blood sugar) reduction with efsitora compared to insulin glargine at week 52.
For the efficacy estimand, efsitora reduced A1C by 1.31% compared to 1.27% for insulin glargine, resulting in an A1C of 6.92% and 6.96%, respectively.
For the treatment-regimen estimand, efsitora reduced A1C by 1.19% compared to ...
